Ali Elbireer
YOU?
Author Swipe
View article: Prevalence and predictors of asymptomatic <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> in a Ugandan population most at risk of HIV transmission
Prevalence and predictors of asymptomatic <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> in a Ugandan population most at risk of HIV transmission Open
The aim of this study was to establish the prevalence of asymptomatic Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in key populations at increased risk of transmission of HIV. Additionally, we aimed to identify the associated …
View article: Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060
Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060 Open
HIV and malaria geographically overlap. HIV protease inhibitors kill malaria parasites in vitro and in vivo, but further evaluation in clinical studies is needed.
View article: Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial Open
NCT00988039.
View article: Test Cost and Test Accuracy in Clinical Laboratories in Kampala, Uganda
Test Cost and Test Accuracy in Clinical Laboratories in Kampala, Uganda Open
There were large differences in accuracy and price across laboratories in Kampala. Price was not associated with quality.
View article: Scaling up <scp>HIV</scp> viral load – lessons from the large‐scale implementation of <scp>HIV</scp> early infant diagnosis and <scp>CD</scp>4 testing
Scaling up <span>HIV</span> viral load – lessons from the large‐scale implementation of <span>HIV</span> early infant diagnosis and <span>CD</span>4 testing Open
Introduction The scale‐up of effective HIV viral load (VL) testing is an urgent public health priority. Implementation of testing is supported by the availability of accurate, nucleic acid based laboratory and point‐of‐care (POC) VL techno…
View article: Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial Open
European and Developing Countries Clinical Trials Partnership, UK Medical Research Council, Institito de Salud Carlos III, Irish Aid, Swedish International Development Cooperation Agency, Instituto Superiore di Sanita, WHO, Merck.